H.A. Yu
12 Papers
4 Citations
H.A. Yu is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 7 publications.
Chat about Author
Papers
1188TiP ORCHARD platform study: Osimertinib + datopotamab deruxtecan (Dato-DXd) cohort in patients (pts) with advanced NSCLC (aNSCLC) who have progressed on first-line (1L) osimertinib
J. De Langen,Byoung Chul Cho,Zofia Piotrowska,Xuan Le,J. Goldberg,Johathan Goldman,Isamu Okamoto,Nicola Hewson,Josephine H. R. Maidment,Kie Hie Tang,Naomi Veney,Jan Cosaert,Jcy Lau,M. Dressman,Helen Ambrose,Jonathan W. Riess,H.A. Yu +16 more
TL;DR: Osimertinib, a third-generation, irreversible epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), is the preferred 1L treatment in EGFRm a NSCLC, with significant improvements in progression-free survival or overall survival vs comparators; however, pts may eventually develop disease progression as mentioned in this paper .
5
329P ORCHARD: Osimertinib + necitumumab in patients (pts) with advanced NSCLC whose disease progressed on first-line (1L) osimertinib
Jonathan W. Riess,J. De Langen,Zofia Piotrowska,J. Goldberg,Johathan Goldman,Isamu Okamoto,Santiago Ponce Aix,Shunsuke Teraoka,H. Ambrose,K. Tang,JT Maidment,B. Merchan Ruiz,Nicola Hewson,Jan Cosaert,H.A. Yu +14 more
TL;DR: Osimertinib is a 3rd generation, irreversible, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with CNS activity as discussed by the authors .
3
1195TiP HERTHENA-Lung02: A randomized phase III study of patritumab deruxtecan vs platinum-based chemotherapy in locally advanced or metastatic EGFR-mutated NSCLC after progression with a third-generation EGFR TKI
TL;DR: HER3-DXd as discussed by the authors is a novel antibody-drug conjugate composed of a human anti-HER3 monoclonal antibody (patritumab) linked to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker.
2
1190TiP Pharmacokinetics, efficacy, and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC)
TL;DR: HER3-DXd as mentioned in this paper is a novel antibody-drug conjugate composed of a human anti-HER3 monoclonal antibody (patritumab) linked to a topoisomerase I inhibitor payload via a stable tetrapeptide-based, tumor-selective, cleavable linker.
1
13P Durvalumab + chemotherapy in patients (pts) with advanced EGFR mutation-positive (EGFRm) NSCLC whose disease progressed on first-line (1L) osimertinib: An ORCHARD study interim analysis
Byoung Chul Cho,M. Ahn,Christina S. Baik,Ruth Vera García,Johathan Goldman,S. Kim,J. Lee,M. Nishio,Santiago Ponce,Ravi Salgia,Shunsuke Teraoka,T Tomohiko Yoshida,H.A. Yu,Helen Ambrose,Jan Cosaert,Ryan J. Hartmaier,Josephine H. R. Maidment,Marek Pluta,Isamu Okamoto +18 more
TL;DR: Osimertinib is third generation, irreversible, CNS-active EGFR-TKI, and preferred 1L treatment in pts with advanced EGFRm NSCLC as mentioned in this paper .
1